CN1268136A - 用作γ－氨基丁酸脑受体配位体的取代4－氧代－二氮杂萘－3－甲酰胺 - Google Patents

用作γ－氨基丁酸脑受体配位体的取代4－氧代－二氮杂萘－3－甲酰胺 Download PDF

Info

Publication number
CN1268136A
CN1268136A CN98808578A CN98808578A CN1268136A CN 1268136 A CN1268136 A CN 1268136A CN 98808578 A CN98808578 A CN 98808578A CN 98808578 A CN98808578 A CN 98808578A CN 1268136 A CN1268136 A CN 1268136A
Authority
CN
China
Prior art keywords
group
naphthyridine
oxo
tetrahydrochysene
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98808578A
Other languages
English (en)
Chinese (zh)
Inventor
帕梅拉·奥尔鲍
罗伯特·W·德西蒙
刘刚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurogen Corp
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of CN1268136A publication Critical patent/CN1268136A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN98808578A 1997-08-25 1998-08-24 用作γ－氨基丁酸脑受体配位体的取代4－氧代－二氮杂萘－3－甲酰胺 Pending CN1268136A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91818097A 1997-08-25 1997-08-25
US08/918,180 1997-08-25

Publications (1)

Publication Number Publication Date
CN1268136A true CN1268136A (zh) 2000-09-27

Family

ID=25439933

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98808578A Pending CN1268136A (zh) 1997-08-25 1998-08-24 用作γ－氨基丁酸脑受体配位体的取代4－氧代－二氮杂萘－3－甲酰胺

Country Status (24)

Country Link
EP (1) EP1007526A1 (https=)
JP (1) JP2001514181A (https=)
KR (1) KR20010023313A (https=)
CN (1) CN1268136A (https=)
AP (1) AP2000001742A0 (https=)
AU (1) AU753800B2 (https=)
BG (1) BG104192A (https=)
BR (1) BR9811362A (https=)
CA (1) CA2301599C (https=)
EG (1) EG21717A (https=)
HU (1) HUP0003258A3 (https=)
IL (1) IL134291A0 (https=)
IS (1) IS5382A (https=)
LV (1) LV12539B (https=)
NO (1) NO20000822L (https=)
NZ (1) NZ502548A (https=)
OA (1) OA11293A (https=)
PE (1) PE130999A1 (https=)
PL (1) PL338783A1 (https=)
SI (1) SI20270A (https=)
SK (1) SK2162000A3 (https=)
TW (1) TW574221B (https=)
WO (1) WO1999010347A1 (https=)
YU (1) YU10500A (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0010308A (pt) * 1999-05-06 2002-01-08 Neurogen Corp Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma doença ou distúrbio associados com o agonismo patogênico, agonismo inverso ou antagonismo do receptor de gabaa, para localizar receptores de gabaa em uma amostra de tecido, para inibir a ligação de um composto de benzodiazepina a um receptor de gabaa e para alterar a atividade da transdução de sinal dos receptores de gabaa, e, composição farmacêutica embalada
AU5289600A (en) 1999-05-25 2000-12-12 Neurogen Corporation 4h-1,4-benzothiazine-2-carboxamides and their use as gaba brain receptor ligands
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
CA2425440C (en) 2000-10-12 2010-04-13 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
JP2004517860A (ja) 2000-10-12 2004-06-17 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
US6919351B2 (en) 2000-10-12 2005-07-19 Merck & Co., Inc. Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
WO2002069948A1 (en) * 2001-03-01 2002-09-12 Pfizer Products Inc. Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders
AR036256A1 (es) 2001-08-17 2004-08-25 Merck & Co Inc Sal sodica de un inhibidor de integrasa del vih, procesos para su preparacion, composiciones farmaceuticas que lo contienen y su uso para la manufactura de un medicamento
EP1467970B1 (en) 2002-01-17 2007-08-22 Merck & Co., Inc. Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
WO2003077857A2 (en) 2002-03-15 2003-09-25 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
WO2004106336A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Process for the preparation and purification of 1,5-naphthyridine-3-carboxyamides
WO2004106334A2 (en) * 2003-05-28 2004-12-09 Pfizer Products Inc. Process for the preparation of 1,5-naphthyridine-3-carboxy amides by direct ester amidation
JP5373613B2 (ja) * 2006-10-16 2013-12-18 バイオノミクス リミテッド 新規な抗不安薬化合物
ES2610508T3 (es) * 2006-11-22 2017-04-27 Clinical Research Associates, Llc Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR204813A1 (es) * 1972-05-08 1976-03-05 Yamanouchi Pharma Co Ltd Proceso para la preparacion de derivados de ampilicina
GB1433774A (en) * 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
US4374138A (en) * 1981-11-13 1983-02-15 Warner-Lambert Company Antibacterial amide compounds, compositions, and methods of use
DD279887A1 (de) * 1987-07-03 1990-06-20 Inst Pharmakologische Forschun Verfahren zur herstellung von d-alpha-(4(1h)-1,5-naphthyridon-3-carboxamido)-benzylpenicillin und anderen beta-lactamantibiotika
DD279875A1 (de) * 1987-07-03 1990-06-20 Inst Pharmakologische Forschun Verfahren zur herstellung von aktivierten carbonsaeureestern
DD295360A5 (de) * 1987-07-03 1991-10-31 Akad Wissenschaften Verfahren zur Herstellung von aktivierten Carbonsäureestern
JPS6461461A (en) * 1987-09-01 1989-03-08 Otsuka Pharma Co Ltd Benzohetero ring derivative

Also Published As

Publication number Publication date
HUP0003258A2 (en) 2001-03-28
LV12539B (en) 2001-01-20
WO1999010347A1 (en) 1999-03-04
EP1007526A1 (en) 2000-06-14
HUP0003258A3 (en) 2001-05-28
AU9117398A (en) 1999-03-16
PL338783A1 (en) 2000-11-20
BR9811362A (pt) 2000-08-22
TW574221B (en) 2004-02-01
NZ502548A (en) 2002-06-28
AU753800B2 (en) 2002-10-31
BG104192A (en) 2001-05-31
IS5382A (is) 2000-02-22
OA11293A (en) 2002-11-19
IL134291A0 (en) 2001-04-30
CA2301599A1 (en) 1999-03-04
NO20000822D0 (no) 2000-02-18
SI20270A (sl) 2000-12-31
JP2001514181A (ja) 2001-09-11
PE130999A1 (es) 1999-12-16
CA2301599C (en) 2003-03-25
LV12539A (en) 2000-10-20
SK2162000A3 (en) 2001-03-12
KR20010023313A (ko) 2001-03-26
YU10500A (sh) 2002-10-18
EG21717A (en) 2002-02-27
NO20000822L (no) 2000-04-13
AP2000001742A0 (en) 2000-02-24

Similar Documents

Publication Publication Date Title
CN1268136A (zh) 用作γ－氨基丁酸脑受体配位体的取代4－氧代－二氮杂萘－3－甲酰胺
CN1288148C (zh) 作为尾加压素ii受体拮抗剂的1,2,3,4－四氢异喹啉的衍生物
CN1070492C (zh) 四环衍生物,制备方法和用途
CN1191249C (zh) 用于治疗、特别是治疗良性前列腺增生的喹啉和喹唑啉化合物
CN1076929A (zh) 某些环烷基和氮杂环烷基吡咯并嘧啶；一类新的γ-氨基丁酸脑受体配位体
CN1694708A (zh) TGFβ的抑制剂
CN1118598A (zh) 吡咯并吡啶衍生物
CN1468216A (zh) 含氮五员环化合物
CN1681789A (zh) 1－吡啶－4－基－脲衍生物
CN1143953A (zh) 某些稠合n-吡咯甲酰苯胺；一类新的脑gaba受体配体
CN1535968A (zh) 四氢吡啶基或哌啶基杂环衍生物
CN1835944A (zh) 作为ccr－5拮抗剂的喹啉酰胺衍生物
CN1127498C (zh) 吡啶衍生物、制备吡啶衍生物的方法及其中间体
CN1863795A (zh) P－糖蛋白抑制剂,其制备方法和包括该抑制剂的药物组合物
CN1250544C (zh) 吡啶并芳基苯基噁唑烷酮抗菌剂和相关组合物及方法
CN1347416A (zh) 取代的3－氰基－[1.7],[1.5]和[1.8]－二氮杂萘酪氨酸激酶抑制剂
CN1934083A (zh) 作为肾素抑制剂用于治疗高血压的5－氨基－4－羟基－7－(1h－吲哚基甲基)－8－甲基壬酰胺衍生物
CN1042632C (zh) 吡啶酮羧酸衍生物、制备它们的中间体及药物组合物
CN1020900C (zh) 制备新的取代n-(3-羟基-4-哌啶基)苯甲酰胺的方法
CN101061108A (zh) 新的4－苯并咪唑－2－基哒嗪－3酮衍生物
CN1310909C (zh) 新型杂芳基衍生物、其制备以及应用
CN1158610A (zh) 可用于治疗的喹喔啉衍生物
CN1930170A (zh) 二氮杂二环壬烯及四氢吡啶衍生物用作肾素抑制剂
CN1752085A (zh) 芳酰肼类化合物及其用于制备免疫抑制剂的用途
CN1277198A (zh) 新型二环氨基吡嗪酮化合物,其制备方法和包含它们的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1030950

Country of ref document: HK